Free tool
FAERS Monitor: Rystiggo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761286 or its brand name (Rystiggo, Rozanolixizumab-Noli). Reports on generic versions are filed under their own applications.
Reports
1,166
Serious
838
72% of reports
Hospitalization
400
Death reported
20
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myasthenia gravis357
- drug ineffective191
- headache175
- diarrhoea131
- fatigue108
- nausea94
- asthenia86
- dyspnoea80
- pyrexia65
- hospitalisation64
- therapeutic response shortened57
- vomiting57
- myasthenia gravis crisis56
- off label use53
- dysphagia50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 41 |
| 2024 | 330 |
| 2025 | 421 |
| 2026 | 374 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,993 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myasthenia gravisSignal | 357 | 834.1 | 762.9 | 283,255 |
| myasthenia gravis crisisSignal | 56 | 708.6 | 545.9 | 37,398 |
| therapeutic response shortenedSignal | 57 | 31.1 | 24.1 | 1,628 |
| dysphagiaSignal | 50 | 9.5 | 7.2 | 374 |
| hospitalisationSignal | 64 | 7.5 | 5.9 | 358 |
| headacheSignal | 175 | 5.0 | 4.4 | 579 |
| astheniaSignal | 86 | 4.1 | 3.4 | 204 |
| diarrhoeaSignal | 131 | 3.7 | 3.1 | 259 |
| pyrexiaSignal | 65 | 3.4 | 2.7 | 109 |
| drug ineffectiveSignal | 191 | 2.6 | 2.3 | 201 |
| dyspnoeaSignal | 80 | 2.5 | 2.1 | 76 |
| fatigueSignal | 108 | 2.5 | 2.1 | 100 |
| vomitingSignal | 57 | 2.2 | 1.7 | 36 |
| nauseaSignal | 94 | 2.1 | 1.8 | 58 |
| off label use | 53 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.